Evicenter
MarkdownMedical informationP&T meetings
Psilocybin (COMP360)

Treatment-resistant depression

Manufacturer
COMPASS Pathways
Last updated
261 sources

Clinical evidence

COMP001

80 evidence topics · 28 sources

Objective
Location and study date
Study dates and identifiers
ItemRegistry record
Other study ID“COMP001”
Study start (actual)“2019-03-01”
Primary completion (actual)“2021-07-30”
Study completion (actual)“2021-09-27”
Results first posted“2023-04-24”
Enrollment by country
Country25 mg10 mg1 mgTotal
United States“32”“32”“32”“96”
Netherlands“17”“16”“17”“50”
United Kingdom“11”“10”“12”“33”
Spain“5”“6”“5”“16”
Ireland“3”“3”“5”“11”
Denmark“3”“2”“3”“8”
Czechia“3”“2”“2”“7”
Canada“2”“2”“2”“6”
Germany“2”“2”“0”“4”
Portugal“1”“0”“1”“2”
Study design
Registered design details
ItemRegistry record
Phase“Phase 2”
Allocation“Randomized”
Intervention model“Parallel Assignment”
Masking“Quadruple”
Primary purpose“Treatment”
Eligibility criteria
Registered eligibility criteria
ItemRegistry record
Inclusion“Diagnosis of TRD”
Exclusion“Other comorbidities”
Ages eligible“18 Years and older”
Healthy volunteers“No”
Exclusion criteria: protocol
CriterionQuoted protocol text
Psychiatric comorbidity“Current or past history of schizophrenia, psychotic disorder (unless substance induced or due to a medical condition), bipolar disorder, delusional disorder, paranoid personality disorder, schizoaffective disorder, borderline personality disorder, or any serious psychiatric comorbidity as assessed by medical history and a structured clinical interview (version 7.0.2 MINI).”
Prior ECT or ketamine“Prior electroconvulsive therapy and/or ketamine for current episode.”
Substance use“Current (within the last year) alcohol or substance abuse as informed by DSM-5 at Screening (V1).”
Suicide risk“Significant suicide risk as defined by (1) suicidal ideation as endorsed on items 4 or 5 on the C-SSRS within the past year, at Screening or at Baseline, or; (2) suicidal behaviors within the past year, or; (3) clinical assessment of significant suicidal risk during subject interview.”
Psychedelic exposure“exposure to psilocybin within the past year and use of psychedelics, such as ayahuasca, during the current depressive episode”
Pregnancy“Women who are pregnant, nursing, or planning a pregnancy.”
Cardiovascular“Cardiovascular conditions: recent stroke (< 1 year from signing of ICF), recent myocardial infarction (< 1 year from signing of ICF), hypertension (blood pressure > 140/90 mmHg) or clinically significant arrhythmia within 1 year of signing the ICF.”
Diabetes“Uncontrolled insulin-dependent diabetes.”
Seizures“Seizure disorder.”
Treatment
Study outcomes
Rationale for using montgomery-åsberg depression rating scale total score as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Actual enrollment: registry record
Enrollment typeParticipants
Actual“233”
Participants analyzed for the primary endpoint
Analysis25 mg10 mg1 mg
Full analysis set (primary)“79”“75”“79”
Per-protocol set (sensitivity)“77”“65”“68”
Description of analysis sets
Results
Participant disposition
Participant flow: registry results
Status25 mg10 mg1 mg
Started“79”“75”“79”
Completed“74”“66”“69”
Not completed“5”“9”“10”
Baseline characteristics
Demographics: registry results
Characteristic25 mg10 mg1 mgTotal
Participants“79”“75”“79”“233”
Age, mean (SD), years“40.2(12.19)”“40.6(12.76)”“38.7(11.71)”“39.8(12.19)”
Age 65 years or older“3”“2”“2”“7”
Female“35”“34”“43”“112”
Male“44”“41”“36”“121”
White“70”“72”“73”“215”
Asian“4”“3”“5”“12”
Black or African American“4”“0”“1”“5”
Efficacy results
Observed MADRS change at Week 3: registry results
Analysis set25 mg10 mg1 mg
Full analysis set, mean (SD)“-12(12.98)”“-8.9(10.94)”“-6.8(11.10)”
Per-protocol set, mean (SD)“-12(12.98)”“-8.9(11.11)”“-6.7(11.18)”
Health-related quality of life and patient-reported outcomes
Safety results
Serious adverse events through Week 12: registry results
Study limitations
Summary: functional unblinding, low-dose comparator without an active treatment, antidepressant washout, Week 3 primary endpoint

The authors state that interpretation is limited by the absence of an active comparator and the possibility of functional unblinding in participants who received a low dose, and that larger and longer trials, including comparison with existing treatments, are required. Published correspondence disputed the description of the trial as double-blind. The primary endpoint was at Week 3, and the authors state that in the 25 mg group, sustained response at 12 weeks was not generally supportive of the primary results. Participants tapered antidepressants at least two weeks before baseline and were asked to remain off them for at least 3 weeks after dosing; a commentary notes that many started other antidepressants after Week 3. The same commentary notes emergent suicidal ideation and behavior in the 25 mg and 10 mg groups and not in the 1 mg group, and the publication reports suicidal ideation or behavior or self-injury in all dose groups.